TCM
PBYI icon

Traynor Capital Management’s Puma Biotechnology PBYI Stock Holding History

Traynor Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8,156
Closed -$318K – 167
2017
Q1 		$318K Sell
8,156
-1,375
-14% -$50.2K 0.18% 108
2016
Q4 		$292K Sell
9,531
-1,441
-13% -$62.3K 0.19% 98
2016
Q3 		$468K Buy
10,972
+2,341
+27% +$118K 0.33% 66
2016
Q2 		$246K Buy
+8,631
New +$270K 0.19% 98

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Traynor Capital Management's PBYI Position: Q2 2017 in Review

Traynor Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 8,156 shares — an estimated $318K sold.

Traynor Capital Management first reported a position in PBYI in Q2 2016 and held it in 4 quarters. The position peaked at $468K in Q3 2016. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

  • Traynor Capital Management reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
  • Traynor Capital Management sold 8,156 Puma Biotechnology shares in Q2 2017, an estimated $318K.
  • Traynor Capital Management first reported a position in Puma Biotechnology in Q2 2016 and held it in 4 quarters.
  • Traynor Capital Management's Puma Biotechnology position peaked at $468K in Q3 2016.
  • 154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on Traynor Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.